Foley adds IP life sciences litigator in Washington, DC
New partner joins from Akin Gump Strauss Hauer & Feld
European Commission proposes ‘single market’ for meds
Proposals include new regulatory protection periods for innovative drugs | Changes are aimed at improving patient access to therapeutics and boosting the EU pharma industry.
Blank Rome adds partner to Washington, DC, practice
First chair litigator served six years at the US Patent and Trademark Office.
Cipla loses fightback over diarrhoea antibiotic
Judge rejects notion that tribunal acted unfairly in royalties dispute with Salix | Indian firm wanted payments on sales of antibiotic | Appeal brought under act with ‘high hurdle to surmount’.
Lawsuit against Celgene, BMS and others moves forward
New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.
J&J hit with suit over Neutrogena products
Canadian firm alleges infringement of patent directed to cosmetic and pharmaceutical formulations | Pharma giant declined a licensing agreement.
Amgen secures five-year ban on psoriasis drug copycat
Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.
SCOTUS deals fresh blow to Novartis’ MS drug patent
Petition to review invalidation of Gilenya patent denied | Novartis challenged decision resulting from a change in judicial panel.
Fed Circuit refuses to revive Parkinson’s disease patent
Precedential decision upholds lower court’s earlier finding | Patent at heart of the dispute covers treatment patch for Parkinson’s.
Moderna secures COVID-19 vaccine delivery win before appeals court
Biotech fails to convince Federal Circuit to overturn PTAB finding | Invalidation of patent related to “Non-liposomal systems for nucleic acid delivery”.
